Get started
Author

Joaquín Gavilá Gregori

Observed names: Gavila Gregori, Joaquin, J. G. Gregori, J. Gavila Gregori, J. Gavilá Gregori, Joaquin Gavila Gregori, Joaquin Gavilá Gregori, Joaquín Gavilà Gregori, Joaquín Gavilá
ORCID: 0000-0002-6768-3833
Observed ORCID: 0000-0002-6768-3833
OpenAlex ID: A5013368807
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
2023 · Fabrice André, Yeon Hee Park, et al. · The Lancet · 416
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
2023 · Francisco Ayala de la Peña, Silvia Antolín Novoa, et al. · Clinical & Translational Oncology · 42
PDF
Defining the optimal sequence for the systemic treatment of metastatic breast cancer
2016 · J. A. Mestres, A. B. iMolins, et al. · Clinical & Translational Oncology · 26
PDF
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
2019 · J. I. Chacón López-Muñiz, L. de la Cruz Merino, et al. · Clinical & Translational Oncology · 24
Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02
2023 · Ian Krop, Yeon H. Park, et al. · Cancer Research · 23
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
2024 · Nadia Harbeck, Eva Ciruelos, et al. · Nature Medicine · 13
PDF
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study
2022 · Virginia Lope, Angel Guerrero-Zotano, et al. · Cancers · 11
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
2022 · Javier Salvador Bofill, Fernando Moreno Anton, et al. · The Breast · 7
PDF
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)
2025 · Francisco Ayala de la Peña, Silvia Antolín Novoa, et al. · Clinical & Translational Oncology · 6
PDF
Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
2025 · Mafalda Oliveira, Eva Ciruelos, et al. · Clinical Cancer Research · 4
PDF
15P The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): A SOLTI biomarker analysis
2020 · B. González-Farré, P. Nuciforo, et al. · Annals of Oncology · 4
2O ERBB3 mRNA expression in breast cancer (BC): A SOLTI biomarker discovery analysis
2020 · T. Pascual, M. Oliveira, et al. · Annals of Oncology · 3
Everolimus in combination with Exemestane in hormone receptor-positive, locally advanced or metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors (NSAIs) : BALLET study (CRAD001YIC04)
2015 · JERUSALEM, Guy, Mariani, Gabriella, et al. · ORBi (University of Liège) · 3
Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients
2009 · Vicente Alberola Candel, Alfredo Carrato Mena, et al. · Clinical & Translational Oncology · 3
La eutanasia en el paciente con cáncer y los cuidados continuos
2005 · Carlos Camps Herrero, Joaquín Gavilá Gregori, et al. · Clinical & Translational Oncology · 3
From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2– breast cancer
2026 · Paulina Stachyra, Cristina Hernando Meliá, et al. · The Breast · 2
PDF
WITHDRAWN: From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2– breast cancer
2026 · Paulina Stachyra, Cristina Hernando Meliá, et al. · The Breast · 2
Abstract PD17-07: Cell-Cycle Inhibition and Immune Microenvironment in HR+/HER2- Breast Cancer During and After preoperative ribociclib and letrozole vesus chemotherapy: A correlative analysis of the 1402-SOLTI/CORALLEEN phase 2 trial
2023 · Tomás Pascual, Nuria Chic, et al. · Cancer Research · 2
41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1)
2020 · L. Manso, P. Villagrasa, et al. · Annals of Oncology · 2
Abstract P5-19-02: Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04)
2015 · Guy Jerusalem, Gabriella Mariani, et al. · Cancer Research · 2
Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
2023 · Francisco Ayala de la Peña, Silvia Antolín Novoa, et al. · Clinical & Translational Oncology · 1
PDF
6P The oncolytic virus pelareorep primes the tumor microenvironment for checkpoint blockade therapy in early breast cancer patients: Results from AWARE-1 study
2022 · J. Gavila Gregori, H. Loghmani, et al. · Annals of Oncology · 1
Abstract OT1-12-09: Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)
2022 · Joaquín Gavilá Gregori, Elena López Miranda, et al. · Cancer Research · 1
4P Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)+/HER2+ breast cancer (BC)
2020 · T. Pascual, A. Fernandez-Martinez, et al. · Annals of Oncology · 1
23P Clinical, pathological and gene expression features of HER2-low breast cancer
2020 · F. Schettini, N. Chic, et al. · Annals of Oncology · 1
PDF
Works count: 34
Citation count: 603
H-index: 7
I10-index: 7
Year
Topic
Type